drugset / Trial / NCT05429385
Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
Phase 1
Withdrawn
Shanghai Henlius Biotech
Hengenix Biotech Inc · collabSanyou Biopharmaceuticals(Shanghai)Co., Ltd · collabShanghai ZJ Bio-Tech Co., Ltd · collab
RandomizedSequentialQuadruple-blindOther
Summary
A single-center, randomized, double-blind, placebo-controlled, dose escalation, phase I clinical study to evaluate safety and pharmacokinetics of HLX70 in healthy adult volunteers
Timeline
- Start
- 2020-12-09
- Primary completion
- 2021-09-06
- Completion
- 2021-09-18
Outcome
Outcome not reported
Stopped (Business): “Sponsor strategy.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX70 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | HLX70 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | HLX70 | Monoclonal antibody | 30 mg/kg | Intravenous |